Cargando…

Development and validation of prediction models for gestational diabetes treatment modality using supervised machine learning: a population-based cohort study

BACKGROUND: Gestational diabetes (GDM) is prevalent and benefits from timely and effective treatment, given the short window to impact glycemic control. Clinicians face major barriers to choosing effectively among treatment modalities [medical nutrition therapy (MNT) with or without pharmacologic tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Liao, Lauren D., Ferrara, Assiamira, Greenberg, Mara B., Ngo, Amanda L., Feng, Juanran, Zhang, Zhenhua, Bradshaw, Patrick T., Hubbard, Alan E., Zhu, Yeyi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9476287/
https://www.ncbi.nlm.nih.gov/pubmed/36104698
http://dx.doi.org/10.1186/s12916-022-02499-7
_version_ 1784790104469929984
author Liao, Lauren D.
Ferrara, Assiamira
Greenberg, Mara B.
Ngo, Amanda L.
Feng, Juanran
Zhang, Zhenhua
Bradshaw, Patrick T.
Hubbard, Alan E.
Zhu, Yeyi
author_facet Liao, Lauren D.
Ferrara, Assiamira
Greenberg, Mara B.
Ngo, Amanda L.
Feng, Juanran
Zhang, Zhenhua
Bradshaw, Patrick T.
Hubbard, Alan E.
Zhu, Yeyi
author_sort Liao, Lauren D.
collection PubMed
description BACKGROUND: Gestational diabetes (GDM) is prevalent and benefits from timely and effective treatment, given the short window to impact glycemic control. Clinicians face major barriers to choosing effectively among treatment modalities [medical nutrition therapy (MNT) with or without pharmacologic treatment (antidiabetic oral agents and/or insulin)]. We investigated whether clinical data at varied stages of pregnancy can predict GDM treatment modality. METHODS: Among a population-based cohort of 30,474 pregnancies with GDM delivered at Kaiser Permanente Northern California in 2007–2017, we selected those in 2007–2016 as the discovery set and 2017 as the temporal/future validation set. Potential predictors were extracted from electronic health records at different timepoints (levels 1–4): (1) 1-year preconception to the last menstrual period, (2) the last menstrual period to GDM diagnosis, (3) at GDM diagnosis, and (4) 1 week after GDM diagnosis. We compared transparent and ensemble machine learning prediction methods, including least absolute shrinkage and selection operator (LASSO) regression and super learner, containing classification and regression tree, LASSO regression, random forest, and extreme gradient boosting algorithms, to predict risks for pharmacologic treatment beyond MNT. RESULTS: The super learner using levels 1–4 predictors had higher predictability [tenfold cross-validated C-statistic in discovery/validation set: 0.934 (95% CI: 0.931–0.936)/0.815 (0.800–0.829)], compared to levels 1, 1–2, and 1–3 (discovery/validation set C-statistic: 0.683–0.869/0.634–0.754). A simpler, more interpretable model, including timing of GDM diagnosis, diagnostic fasting glucose value, and the status and frequency of glycemic control at fasting during one-week post diagnosis, was developed using tenfold cross-validated logistic regression based on super learner-selected predictors. This model compared to the super learner had only a modest reduction in predictability [discovery/validation set C-statistic: 0.825 (0.820–0.830)/0.798 (95% CI: 0.783–0.813)]. CONCLUSIONS: Clinical data demonstrated reasonably high predictability for GDM treatment modality at the time of GDM diagnosis and high predictability at 1-week post GDM diagnosis. These population-based, clinically oriented models may support algorithm-based risk-stratification for treatment modality, inform timely treatment, and catalyze more effective management of GDM. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12916-022-02499-7.
format Online
Article
Text
id pubmed-9476287
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-94762872022-09-16 Development and validation of prediction models for gestational diabetes treatment modality using supervised machine learning: a population-based cohort study Liao, Lauren D. Ferrara, Assiamira Greenberg, Mara B. Ngo, Amanda L. Feng, Juanran Zhang, Zhenhua Bradshaw, Patrick T. Hubbard, Alan E. Zhu, Yeyi BMC Med Research Article BACKGROUND: Gestational diabetes (GDM) is prevalent and benefits from timely and effective treatment, given the short window to impact glycemic control. Clinicians face major barriers to choosing effectively among treatment modalities [medical nutrition therapy (MNT) with or without pharmacologic treatment (antidiabetic oral agents and/or insulin)]. We investigated whether clinical data at varied stages of pregnancy can predict GDM treatment modality. METHODS: Among a population-based cohort of 30,474 pregnancies with GDM delivered at Kaiser Permanente Northern California in 2007–2017, we selected those in 2007–2016 as the discovery set and 2017 as the temporal/future validation set. Potential predictors were extracted from electronic health records at different timepoints (levels 1–4): (1) 1-year preconception to the last menstrual period, (2) the last menstrual period to GDM diagnosis, (3) at GDM diagnosis, and (4) 1 week after GDM diagnosis. We compared transparent and ensemble machine learning prediction methods, including least absolute shrinkage and selection operator (LASSO) regression and super learner, containing classification and regression tree, LASSO regression, random forest, and extreme gradient boosting algorithms, to predict risks for pharmacologic treatment beyond MNT. RESULTS: The super learner using levels 1–4 predictors had higher predictability [tenfold cross-validated C-statistic in discovery/validation set: 0.934 (95% CI: 0.931–0.936)/0.815 (0.800–0.829)], compared to levels 1, 1–2, and 1–3 (discovery/validation set C-statistic: 0.683–0.869/0.634–0.754). A simpler, more interpretable model, including timing of GDM diagnosis, diagnostic fasting glucose value, and the status and frequency of glycemic control at fasting during one-week post diagnosis, was developed using tenfold cross-validated logistic regression based on super learner-selected predictors. This model compared to the super learner had only a modest reduction in predictability [discovery/validation set C-statistic: 0.825 (0.820–0.830)/0.798 (95% CI: 0.783–0.813)]. CONCLUSIONS: Clinical data demonstrated reasonably high predictability for GDM treatment modality at the time of GDM diagnosis and high predictability at 1-week post GDM diagnosis. These population-based, clinically oriented models may support algorithm-based risk-stratification for treatment modality, inform timely treatment, and catalyze more effective management of GDM. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12916-022-02499-7. BioMed Central 2022-09-15 /pmc/articles/PMC9476287/ /pubmed/36104698 http://dx.doi.org/10.1186/s12916-022-02499-7 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Liao, Lauren D.
Ferrara, Assiamira
Greenberg, Mara B.
Ngo, Amanda L.
Feng, Juanran
Zhang, Zhenhua
Bradshaw, Patrick T.
Hubbard, Alan E.
Zhu, Yeyi
Development and validation of prediction models for gestational diabetes treatment modality using supervised machine learning: a population-based cohort study
title Development and validation of prediction models for gestational diabetes treatment modality using supervised machine learning: a population-based cohort study
title_full Development and validation of prediction models for gestational diabetes treatment modality using supervised machine learning: a population-based cohort study
title_fullStr Development and validation of prediction models for gestational diabetes treatment modality using supervised machine learning: a population-based cohort study
title_full_unstemmed Development and validation of prediction models for gestational diabetes treatment modality using supervised machine learning: a population-based cohort study
title_short Development and validation of prediction models for gestational diabetes treatment modality using supervised machine learning: a population-based cohort study
title_sort development and validation of prediction models for gestational diabetes treatment modality using supervised machine learning: a population-based cohort study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9476287/
https://www.ncbi.nlm.nih.gov/pubmed/36104698
http://dx.doi.org/10.1186/s12916-022-02499-7
work_keys_str_mv AT liaolaurend developmentandvalidationofpredictionmodelsforgestationaldiabetestreatmentmodalityusingsupervisedmachinelearningapopulationbasedcohortstudy
AT ferraraassiamira developmentandvalidationofpredictionmodelsforgestationaldiabetestreatmentmodalityusingsupervisedmachinelearningapopulationbasedcohortstudy
AT greenbergmarab developmentandvalidationofpredictionmodelsforgestationaldiabetestreatmentmodalityusingsupervisedmachinelearningapopulationbasedcohortstudy
AT ngoamandal developmentandvalidationofpredictionmodelsforgestationaldiabetestreatmentmodalityusingsupervisedmachinelearningapopulationbasedcohortstudy
AT fengjuanran developmentandvalidationofpredictionmodelsforgestationaldiabetestreatmentmodalityusingsupervisedmachinelearningapopulationbasedcohortstudy
AT zhangzhenhua developmentandvalidationofpredictionmodelsforgestationaldiabetestreatmentmodalityusingsupervisedmachinelearningapopulationbasedcohortstudy
AT bradshawpatrickt developmentandvalidationofpredictionmodelsforgestationaldiabetestreatmentmodalityusingsupervisedmachinelearningapopulationbasedcohortstudy
AT hubbardalane developmentandvalidationofpredictionmodelsforgestationaldiabetestreatmentmodalityusingsupervisedmachinelearningapopulationbasedcohortstudy
AT zhuyeyi developmentandvalidationofpredictionmodelsforgestationaldiabetestreatmentmodalityusingsupervisedmachinelearningapopulationbasedcohortstudy